The regulation of food intake by the gut-brain axis: Implications for obesity

International Journal of Obesity

Volumn 37, Issue 5, 2013, Pages 625-633

  Hussain, S S ^a   Bloom, S R ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

anti obesity agents; appetite; food intake; gut hormones

Indexed keywords

AMFEBUTAMONE PLUS NALTREXONE; AMYLIN; ANTIOBESITY AGENT; CHOLECYSTOKININ; DEXFENFLURAMINE; FENFLURAMINE; GHRELIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; LORCASERIN; OXYNTOMODULIN; PANCREAS POLYPEPTIDE; PEPTIDE YY; PHENTERMINE PLUS TOPIRAMATE; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

APPETITE; BRAIN STEM; CLINICAL TRIAL; DRUG SAFETY; ENERGY BALANCE; FOOD INTAKE; HOMEOSTASIS; HUMAN; LEARNING; OBESITY; PRIORITY JOURNAL; REVIEW;

APPETITE REGULATION; AUTONOMIC PATHWAYS; EATING; FEMALE; GASTROINTESTINAL TRACT; HOMEOSTASIS; HUMANS; HYPOTHALAMUS; LEPTIN; MALE; OBESITY; PEPTIDE HORMONES; SATIATION; SIGNAL TRANSDUCTION;

EID: 84877577992     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2012.93     Document Type: Review

References (138)

1. Brobeck JR. Mechanism of the development of obesity in animals with hypothalamic lesions. Physiol Rev 1946; 26: 541-559.
2. Speakman JR, Levitsky DA, Allison DB, Bray MS, de Castro JM, Clegg DJ et al. Set points, settling points and some alternative models: theoretical options to understand how genes and environments combine to regulate body adiposity. Dis Model Mech 2011; 4: 733-745.
3. Schwartz MW, Woods SC, Porte Jr D, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature 2000; 404: 661-671.
4. Berthoud HR. Homeostatic and non-homeostatic pathways involved in the control of food intake and energy balance. Obesity (Silver Spring) 2006; 14(Suppl 5): 197S-200S.
5. Beck B. KO's and organisation of peptidergic feeding behavior mechanisms. Neurosci Biobehav Rev 2001; 25: 143-158.
6. Schwartz MW. Central nervous system regulation of food intake. Obesity (Silver Spring) 2006; 14(Suppl 1): 1S-8S.
7. Hussain SS, Bloom SR. The pharmacological treatment and management of obesity. Postgrad Med 2011; 123: 34-44.
8. Konner AC, Klockener T, Bruning JC. Control of energy homeostasis by insulin and leptin: targeting the arcuate nucleus and beyond. Physiol Behav 2009; 97: 632-638.
9. Broadwell RD, Brightman MW. Entry of peroxidase into neurons of the central and peripheral nervous systems from extracerebral and cerebral blood. J Comp Neurol 1976; 166: 257-283.
10. Peruzzo B, Pastor FE, Blazquez JL, Schobitz K, Pelaez B, Amat P et al. A second look at the barriers of the medial basal hypothalamus. Exp Brain Res 2000; 132: 10-26.
11. Kalra SP, Dube MG, Pu S, Xu B, Horvath TL, Kalra PS. Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr Rev 1999; 20: 68-100.
12. Bouret SG, Draper SJ, Simerly RB. Formation of projection pathways from the arcuate nucleus of the hypothalamus to hypothalamic regions implicated in the neural control of feeding behavior in mice. J Neurosci 2004; 24: 2797-2805.
13. Cone RD, Cowley MA, Butler AA, Fan W, Marks DL, Low MJ. The arcuate nucleus as a conduit for diverse signals relevant to energy homeostasis. Int J Obes Relat Metab Disord 2001; 25(Suppl 5): S63-S67.
14. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G proteincoupled receptors that regulate feeding behavior. Cell 1998; 92: 573-585.
15. Qu D, Ludwig DS, Gammeltoft S, Piper M, Pelleymounter MA, Cullen MJ et al. A role for melanin-concentrating hormone in the central regulation of feeding behaviour. Nature 1996; 380: 243-247.
16. Rossi M, Choi SJ, O'Shea D, Miyoshi T, Ghatei MA, Bloom SR. Melanin-concentrating hormone acutely stimulates feeding, but chronic administration has no effect on body weight. Endocrinology 1997; 138: 351-355.
17. Xu B, Goulding EH, Zang K, Cepoi D, Cone RD, Jones KR et al. Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor. Nat Neurosci 2003; 6: 736-742.
18. Dhillon H, Zigman JM, Ye C, Lee CE, McGovern RA, Tang V et al. Leptin directly activates SF1 neurons in the VMH, and this action by leptin is required for normal body-weight homeostasis. Neuron 2006; 49: 191-203.
19. Lam TK, Schwartz GJ, Rossetti L. Hypothalamic sensing of fatty acids. Nat Neurosci 2005; 8: 579-584.
20. Jordan SD, Konner AC, Bruning JC. Sensing the fuels: glucose and lipid signaling in the CNS controlling energy homeostasis. Cell Mol Life Sci 2010; 67: 3255-3273.
21. Levin BE, Magnan C, Dunn-Meynell A, Le Foll C. Metabolic sensing and the brain: who, what, where, and how? Endocrinology 2011; 152: 2552-2557.
22. Grill HJ, Kaplan JM. The neuroanatomical axis for control of energy balance. Front Neuroendocrinol 2002; 23: 2-40.
23. Blevins JE, Baskin DG. Hypothalamic-brainstem circuits controlling eating. Forum Nutr 2010; 63: 133-140.
24. Grill HJ, Schwartz MW, Kaplan JM, Foxhall JS, Breininger J, Baskin DG. Evidence that the caudal brainstem is a target for the inhibitory effect of leptin on food intake. Endocrinology 2002; 143: 239-246.
25. Lebrun B, Bariohay B, Moyse E, Jean A. Brain-derived neurotrophic factor (BDNF) and food intake regulation: a minireview. Auton Neurosci 2006; 126-127: 30-38.
26. Chaudhri O, Small C, Bloom S. Gastrointestinal hormones regulating appetite. Philos Trans R Soc Lond B Biol Sci 2006; 361: 1187-1209.
27. Schwartz GJ. The role of gastrointestinal vagal afferents in the control of food intake: current prospects. Nutrition 2000; 16: 866-873.
28. Price CJ, Hoyda TD, Ferguson AV. The area postrema: a brain monitor and integrator of systemic autonomic state. Neuroscientist 2008; 14: 182-194.
29. Ter Horst GJ, de Boer P, Luiten PG, van Willigen JD. Ascending projections from the solitary tract nucleus to the hypothalamus. A Phaseolus vulgaris lectin tracing study in the rat. Neuroscience 1989; 31: 785-797.
30. ter Horst GJ, Luiten PG, Kuipers F. Descending pathways from hypothalamus to dorsal motor vagus and ambiguus nuclei in the rat. J Auton Nerv Syst 1984; 11: 59-75.
31. Grijalva CV, Novin D. The role of the hypothalamus and dorsal vagal complex in gastrointestinal function and pathophysiology. Ann NY Acad Sci 1990; 597: 207-222.
32. Grill HJ, Skibicka KP, Hayes MR. Imaging obesity: fMRI, food reward, and feeding. Cell Metab 2007; 6: 423-425.
33. De Silva A, Salem V, Long CJ, Makwana A, Newbould RD, Rabiner EA et al. The gut hormones PYY(3-36) and GLP-1(7-36 amide) reduce food intake and modulate brain activity in appetite centers in humans. Cell Metab 2011; 14: 700-706.
34. Page KA, Seo D, Belfort-DeAguiar R, Lacadie C, Dzuira J, Naik S et al. Circulating glucose levels modulate neural control of desire for high-calorie foods in humans. J Clin Invest 2011; 121: 4161-4169.
35. Velloso LA, Schwartz MW. Altered hypothalamic function in diet-induced obesity. Int J Obes (Lond) 2011; 35: 1455-1465.
36. Raben A, Astrup A. Leptin is influenced both by predisposition to obesity and diet composition. Int J Obes Relat Metab Disord 2000; 24: 450-459.
37. Murphy KG, Bloom SR. Gut hormones and the regulation of energy homeostasis. Nature 2006; 444: 854-859.
38. Rolls ET. Brain mechanisms underlying flavour and appetite. Philos Trans R Soc Lond B Biol Sci 2006; 361: 1123-1136.
39. Schwartz GJ. Brainstem integrative function in the central nervous system control of food intake. Forum Nutr 2010; 63: 141-151.
40. Gibbs J, Young RC, Smith GP. Cholecystokinin decreases food intake in rats. J Comp Physiol Psychol 1973; 84: 488-495.
41. Kissileff HR, Pi-Sunyer FX, Thornton J, Smith GP. C-terminal octapeptide of cholecystokinin decreases food intake in man. Am J Clin Nutr 1981; 34: 154-160.
42. Buffa R, Solcia E, Go VL. Immunohistochemical identification of the cholecystokinin cell in the intestinal mucosa. Gastroenterology 1976; 70: 528-532.
43. Liddle RA, Goldfine ID, Rosen MS, Taplitz RA, Williams JA. Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction. J Clin Invest 1985; 75: 1144-1152.
44. Rehfeld JF, Bungaard JR, Friis-Hansen L, Goetze JP. On the tissue-specific processing of procholecystokinin in the brain and gut-a short review. J Physiol Pharmacol 2003; 54(Suppl 4): 73-79.
45. Moran TH, Ameglio PJ, Schwartz GJ, McHugh PR. Blockade of type A, not type B, CCK receptors attenuates satiety actions of exogenous and endogenous CCK. Am J Physiol 1992; 262(1 Pt 2): R46-R50.
46. Zittel TT, Glatzle J, Kreis ME, Starlinger M, Eichner M, Raybould HE et al. C-fos protein expression in the nucleus of the solitary tract correlates with cholecystokinin dose injected and food intake in rats. Brain Res 1999; 846: 1-11.
47. Blevins JE, Stanley BG, Reidelberger RD. Brain regions where cholecystokinin suppresses feeding in rats. Brain Res 2000; 860: 1-10.
48. Moran TH, Katz LF, Plata-Salaman CR, Schwartz GJ. Disordered food intake and obesity in rats lacking cholecystokinin A receptors. Am J Physiol 1998; 274(3 Pt 2): R618-R625.
49. Kopin AS, Mathes WF, McBride EW, Nguyen M, Al-Haider W, Schmitz F et al. The cholecystokinin-A receptor mediates inhibition of food intake yet is not essential for the maintenance of body weight. J Clin Invest 1999; 103: 383-391.
50. Crawley JN, Beinfeld MC. Rapid development of tolerance to the behavioural actions of cholecystokinin. Nature 1983; 302: 703-706.
51. West DB, Fey D, Woods SC. Cholecystokinin persistently suppresses meal size but not food intake in free-feeding rats. Am J Physiol 1984; 246(5 Pt 2): R776-R787.
52. West DB, Greenwood MR, Sullivan AC, Prescod L, Marzullo LR, Triscari J. Infusion of cholecystokinin between meals into free-feeding rats fails to prolong the intermeal interval. Physiol Behav 1987; 39: 111-115.
53. Kojima M, Kangawa K. Ghrelin: structure and function. Physiol Rev 2005; 85: 495-522.
54. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656-660.
55. Patterson M, Bloom SR, Gardiner JV. Ghrelin and appetite control in humans-Potential application in the treatment of obesity. Peptides 2011; 32: 2290-2294.
56. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001; 50: 1714-1719.
57. Tschop M, Wawarta R, Riepl RL, Friedrich S, Bidlingmaier M, Landgraf R et al. Post-prandial decrease of circulating human ghrelin levels. J Endocrinol Invest 2001; 24: RC19-RC21.
58. Ariyasu H, Takaya K, Tagami T, Ogawa Y, Hosoda K, Akamizu T et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab 2001; 86: 4753-4758.
59. Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001; 86: 5992.
60. Wren AM, Small CJ, Abbott CR, Dhillo WS, Seal LJ, Cohen MA et al. Ghrelin causes hyperphagia and obesity in rats. Diabetes 2001; 50: 2540-2547.
61. Castaneda TR, Tong J, Datta R, Culler M, Tschop MH. Ghrelin in the regulation of body weight and metabolism. Front Neuroendocrinol 2010; 31: 44-60.
62. Lawrence CB, Snape AC, Baudoin FM, Luckman SM. Acute central ghrelin and GH secretagogues induce feeding and activate brain appetite centers. Endocrinology 2002; 143: 155-162.
63. Chuang JC, Perello M, Sakata I, Osborne-Lawrence S, Savitt JM, Lutter M et al. Ghrelin mediates stress-induced food-reward behavior in mice. J Clin Invest 2011; 121: 2684-2692.
64. Tschop M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001; 50: 707-709.
65. Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002; 346: 1623-1630.
66. Gardiner JV, Campbell D, Patterson M, Kent A, Ghatei MA, Bloom SR et al. The hyperphagic effect of ghrelin is inhibited in mice by a diet high in fat. Gastroenterology 2010; 138: 2468-2476, 2476.e1.
67. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 1985; 89: 1070-1077.
68. Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349: 941-948.
69. Batterham RL, Heffron H, Kapoor S, Chivers JE, Chandarana K, Herzog H et al. Critical role for peptide YY in protein-mediated satiation and body-weight regulation. Cell Metab 2006; 4: 223-233.
70. Vincent RP, le Roux CW. Changes in gut hormones after bariatric surgery. Clin Endocrinol (Oxf) 2008; 69: 173-179.
71. Chandarana K, Gelegen C, Karra E, Choudhury AI, Drew ME, Fauveau V et al. Diet and gastrointestinal bypass-induced weight loss: the roles of ghrelin and peptide YY. Diabetes 2011; 60: 810-818.
72. Vrang N, Madsen AN, Tang-Christensen M, Hansen G, Larsen PJ. PYY(3-36) reduces food intake and body weight and improves insulin sensitivity in rodent models of diet-induced obesity. Am J Physiol Regul Integr Comp Physiol 2006; 291: R367-R375.
73. Degen L, Oesch S, Casanova M, Graf S, Ketterer S, Drewe J et al. Effect of peptide YY3-36 on food intake in humans. Gastroenterology 2005; 129: 1430-1436.
74. Sloth B, Holst JJ, Flint A, Gregersen NT, Astrup A. Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects. Am J Physiol Endocrinol Metab 2007; 292: E1062-E1068.
75. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002; 418: 650-654.
76. Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D et al. XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol Rev 1998; 50: 143-150.
77. Schmidt PT, Naslund E, Gryback P, Jacobsson H, Holst JJ, Hilsted L et al. A role for pancreatic polypeptide in the regulation of gastric emptying and short-term metabolic control. J Clin Endocrinol Metab 2005; 90: 5241-5246.
78. Asakawa A, Inui A, Ueno N, Fujimiya M, Fujino MA, Kasuga M. Mouse pancreatic polypeptide modulates food intake, while not influencing anxiety in mice. Peptides 1999; 20: 1445-1448.
79. Batterham RL, Le Roux CW, Cohen MA, Park AJ, Ellis SM, Patterson M et al. Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab 2003; 88: 3989-3992.
80. Hankir MK, Parkinson JR, Minnion JS, Addison ML, Bloom SR, Bell JD. Peptide YY 3-36 and pancreatic polypeptide differentially regulate hypothalamic neuronal activity in mice in vivo as measured by manganese-enhanced magnetic resonance imaging. J Neuroendocrinol 2011; 23: 371-380.
81. Dhanvantari S, Seidah NG, Brubaker PL. Role of prohormone convertases in the tissue-specific processing of proglucagon. Mol Endocrinol 1996; 10: 342-355.
82. Herrmann C, Goke R, Richter G, Fehmann HC, Arnold R, Goke B. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 1995; 56: 117-126.
83. Rocca AS, Brubaker PL. Role of the vagus nerve in mediating proximal nutrientinduced glucagon-like peptide-1 secretion. Endocrinology 1999; 140: 1687-1694.
84. Chu ZL, Carroll C, Alfonso J, Gutierrez V, He H, Lucman A et al. A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release. Endocrinology 2008; 149: 2038-2047.
85. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987; 2: 1300-1304.
86. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3: 153-165.
87. Parkinson JR, Chaudhri OB, Kuo YT, Field BC, Herlihy AH, Dhillo WS et al. Differential patterns of neuronal activation in the brainstem and hypothalamus following peripheral injection of GLP-1, oxyntomodulin and lithium chloride in mice detected by manganese-enhanced magnetic resonance imaging (MEMRI). Neuroimage 2009; 44: 1022-1031.
88. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992; 267: 7402-7405.
89. Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011; CD006423.
90. Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 2011; e-pub ahead of print 16 August 2011; doi:10.1038/ijo.2011.158.
91. Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012; 344: d7771.
92. Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010; 59: 1030-1037.
93. Jin SL, Han VK, Simmons JG, Towle AC, Lauder JM, Lund PK. Distribution of glucagonlike peptide I (GLP-I), glucagon, and glicentin in the rat brain: an immunocytochemical study. J Comp Neurol 1988; 271: 519-532.
94. Le Quellec A, Kervran A, Blache P, Ciurana AJ, Bataille D. Oxyntomodulin-like immunoreactivity: diurnal profile of a new potential enterogastrone. J Clin Endocrinol Metab 1992; 74: 1405-1409.
95. Baggio LL, Huang Q, Brown TJ, Drucker DJ. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 2004; 127: 546-558.
96. Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Oxyntomodulin from distal gut. Role in regulation of gastric and pancreatic functions. Dig Dis Sci 1989; 34: 1411-1419.
97. Wynne K, Park AJ, Small CJ, Meeran K, Ghatei MA, Frost GS et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes (Lond) 2006; 30: 1729-1736.
98. Chaudhri OB, Parkinson JR, Kuo YT, Druce MR, Herlihy AH, Bell JD et al. Differential hypothalamic neuronal activation following peripheral injection of GLP-1 and oxyntomodulin in mice detected by manganese-enhanced magnetic resonance imaging. Biochem Biophys Res Commun 2006; 350: 298-306.
99. Dakin CL, Small CJ, Batterham RL, Neary NM, Cohen MA, Patterson M et al. Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 2004; 145: 2687-2695.
100. Svoboda M, Tastenoy M, Vertongen P, Robberecht P. Relative quantitative analysis of glucagon receptor mRNA in rat tissues. Mol Cell Endocrinol 1994; 105: 131-137.
101. Woods SC, Lutz TA, Geary N, Langhans W. Pancreatic signals controlling food intake; insulin, glucagon and amylin. Philos Trans R Soc Lond B Biol Sci 2006; 361: 1219-1235.
102. Schulman JL, Carleton JL, Whitney G, Whitehorn JC. Effect of glucagon on food intake and body weight in man. J Appl Physiol 1957; 11: 419-421.
103. de Castro JM, Paullin SK, DeLugas GM. Insulin and glucagon as determinants of body weight set point and microregulation in rats. J Comp Physiol Psychol 1978; 92: 571-579.
104. Langhans W, Zeiger U, Scharrer E, Geary N. Stimulation of feeding in rats by intraperitoneal injection of antibodies to glucagon. Science 1982; 218: 894-896.
105. Habegger KM, Heppner KM, Geary N, Bartness TJ, DiMarchi R, Tschop MH. The metabolic actions of glucagon revisited. Nat Rev Endocrinol 2010; 6: 689-697.
106. Pocai A, Carrington PE, Adams JR, Wright M, Eiermann G, Zhu L et al. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes 2009; 58: 2258-2266.
107. Day JW, Ottaway N, Patterson JT, Gelfanov V, Smiley D, Gidda J et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 2009; 5: 749-757.
108. Bailey RJ, Walker CS, Ferner AH, Loomes KM, Prijic G, Halim A et al. Pharmacological characterisation of rat amylin receptors: implications for the identification of amylin receptor subtypes. Br J Pharmacol 2011; Oct: 20.
109. Hollander P, Maggs DG, Ruggles JA, Fineman M, Shen L, Kolterman OG et al. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res 2004; 12: 661-668.
110. Mustain WC, Rychahou PG, Evers BM. The role of neurotensin in physiologic and pathologic processes. Curr Opin Endocrinol Diabetes Obes 2011; 18: 75-82.
111. Cui H, Cai F, Belsham DD. Anorexigenic hormones leptin, insulin, and alphamelanocyte-stimulating hormone directly induce neurotensin (NT) gene expression in novel NT-expressing cell models. J Neurosci 2005; 25: 9497-9506.
112. Kim ER, Leckstrom A, Mizuno TM. Impaired anorectic effect of leptin in neurotensin receptor 1-deficient mice. Behav Brain Res 2008; 194: 66-71.
113. Cooke JH, Patterson M, Patel SR, Smith KL, Ghatei MA, Bloom SR et al. Peripheral and central administration of xenin and neurotensin suppress food intake in rodents. Obesity (Silver Spring) 2009; 17: 1135-1143.
114. Zhang JV, Ren PG, Avsian-Kretchmer O, Luo CW, Rauch R, Klein C et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 2005; 310: 996-999.
115. Li JB, Asakawa A, Cheng K, Li Y, Chaolu H, Tsai M et al. Biological effects of obestatin. Endocrine 2011; 39: 205-211.
116. Damholt AB, Buchan AM, Holst JJ, Kofod H. Proglucagon processing profile in canine L cells expressing endogenous prohormone convertase 1/3 and prohormone convertase 2. Endocrinology 1999; 140: 4800-4808.
117. Tang-Christensen M, Larsen PJ, Thulesen J, Romer J, Vrang N. The proglucagonderived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake. Nat Med 2000; 6: 802-807.
118. Scott RB, Kirk D, MacNaughton WK, Meddings JB. GLP-2 augments the adaptive response to massive intestinal resection in rat. Am J Physiol 1998; 275(5 Pt 1): G911-G921.
119. Schmidt PT, Naslund E, Gryback P, Jacobsson H, Hartmann B, Holst JJ et al. Peripheral administration of GLP-2 to humans has no effect on gastric emptying or satiety. Regul Pept 2003; 116: 21-25.
120. Wadden TA, Butryn ML, Wilson C. Lifestyle modification for the management of obesity. Gastroenterology 2007; 132: 2226-2238.
121. Alhassan S, Kim S, Bersamin A, King AC, Gardner CD. Dietary adherence and weight loss success among overweight women: results from the A TO Z weight loss study. Int J Obes (Lond) 2008; 32: 985-991.
122. Johnson PM, Kenny PJ. Dopamine D2 receptors in addiction-like reward dysfunction and compulsive eating in obese rats. Nat Neurosci 2010; 13: 635-641.
123. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007; 335: 1194-1199.
124. Richelsen B, Tonstad S, Rossner S, Toubro S, Niskanen L, Madsbad S et al. Effect of orlistat on weight regain and cardiovascular risk factors following a very-lowenergy diet in abdominally obese patients: a 3-year randomized, placebocontrolled study. Diabetes Care 2007; 30: 27-32.
125. Padwal R, Kezouh A, Levine M, Etminan M. Long-term persistence with orlistat and sibutramine in a population-based cohort. Int J Obes (Lond) 2007; 31: 1567-1570.
126. Pinder RM, Brogden RN, Sawyer PR, Speight TM, Avery GS. Fenfluramine: a review of its pharmacological properties and therapeutic efficacy in obesity. Drugs 1975; 10: 241-323.
127. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337: 581-588.
128. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389-1397.
129. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007; 370: 1706-1713.
130. Torp-Pedersen C, Caterson I, Coutinho W, Finer N, Van Gaal L, Maggioni A et al. Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J 2007; 28: 2915-2923.
131. James WPT, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP et al. Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects. New Engl J Med 2010; 363: 905-917.
132. Kokoeva MV, Yin H, Flier JS. Neurogenesis in the hypothalamus of adult mice: potential role in energy balance. Science 2005; 310: 679-683.
133. Lambert PD, Anderson KD, Sleeman MW, Wong V, Tan J, Hijarunguru A et al. Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity. Proc Natl Acad Sci USA 2001; 98: 4652-4657.
134. Ettinger MP, Littlejohn TW, Schwartz SL, Weiss SR, McIlwain HH, Heymsfield SB et al. Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study. JAMA 2003; 289: 1826-1832.
135. Sjostrom L. Bariatric surgery and reduction in morbidity and mortality: experiences from the SOS study. Int J Obes (Lond) 2008; 32(Suppl 7): S93-S97.
136. Powell AG, Apovian CM, Aronne LJ. New drug targets for the treatment of obesity. Clin Pharmacol Ther 2011; 90: 40-51.
137. Neary NM, Small CJ, Druce MR, Park AJ, Ellis SM, Semjonous NM et al. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology 2005; 146: 5120-5127.
138. Field BC, Wren AM, Peters V, Baynes KC, Martin NM, Patterson M et al. PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans. Diabetes 2010; 59: 1635-1639.